High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/MspI-GSTM1*0/*0 genotypes

Pharmacogenetics

Volumn 8, Issue 2, 1998, Pages 109-118

  Rojas, M ^a   Alexandrov, K ^a   Cascorbi, I ^b   Brockmoller J ^b   Likhachev, A ^c   Pozharisski, K ^c   Bouvier, G ^a   Auburtin, G ^d   Mayer, L ^d   Kopp Schneider, A ^a   Roots, I ^b   Bartsch, H ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^d Lab Biochim Toxicologie in Vitro   (France)

Author keywords

Benzo a pyrene DNA adducts; Coke oven workers; CYP1A1; Genetic polymorphism; GSTM1; Lung cancer; Smokers

Indexed keywords

BENZO[A]PYRENE; ETHOXYRESORUFIN DEETHYLASE; POLYCYCLIC AROMATIC HYDROCARBON;

ARTICLE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DNA DETERMINATION; FEMALE; FLUOROMETRY; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LEUKOCYTE; LUNG CANCER; MALE; MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING;

EID: 15444345746     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199804000-00003     Document Type: Article

References (51)

1. Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Ranung A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 1994; 15:1785-1790.
2. Alexandrov K, Rojas M, Geneste O, Castegnaro M, Camus AM, Petruzzelli S, Giuntini C, Bartsch H. An improved fluorometric assay for dosimetry of benzo[a]pyrene diol-epoxide-DNA adducts in smoker's lung: comparison with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res 1992; 52:6248-6253.
3. Anttila S, Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Nurminen T, Vainio H. Combined effect of CYP1A1 inducibility and GSTM1 polymorphism on histological type of lung cancer. Carcinogenesis 1994; 15:1133-1135.
4. Bartsch H, Hietanen K, Petruzzelli S, Giuntini C, Saracci R, Mussi A, Angeletti CA. Possible prognostic value of pulmonary AH-locus-linked enzymes in patients with tobacco-related lung cancer. Int J Cancer 1990; 46:185-188.
5. Bartsch H, Petruzzelli S, De Flora S, Hietanen E, Camus A-M, Castegnaro M, Alexandrov K, Rojas M, Saracci C, Giuntini C. Carcinogen metabolism in human lung tissues and the effect of tobacco smoking: results from a case-control multicenter study on lung cancer patients. Environ Health Perspect 1992; 98:119-124.
6. Bartsch H. DNA adducts in human carcinogenesis: etiological relevance and structure-activity relationship. Mutation Res 1996; 340:67-79.
7. Brockmöller J, Kerb R, Drakoulis N, Nitz M, Roots I. Genotype and phenotype of glutathione S-transferase class μ isoenzymes in lung cancer patients and controls. Cancer Res 1993; 53: 1004-1011.
8. Brockmöller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferase M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996; 56:3915-3925.
9. Cascorbi I, Brockmöller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996; 56: 4965-4969.
10. Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, Garte SJ. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994; 15:2961-2963.
11. Denissenko MF, Pao A, Tang MS, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 1996; 274:430-432.
12. Drakoulis N, Cascorbi I, Brockmöller J, Gross CR, Roots I. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and aT to C mutation in the 3′-flanking region. Clin Invest 1994; 72: 240-248.
13. Figueras JT, Gene M, Gomez-Catalan J, Galan C, Firvida J, Fuentes M, Rodamilans M, Huguet E, Estape J, Corbella J. Glutathione-S-transferase M1 and codon 72 p53 polymorphisms in a Northwestern mediterranean population and their relation to lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1996; 5:337-342.
14. Grinberg-Funes RA, Singh VN, Perera FP, Bell DA, Young TL, Dickey C, Wang LW, Santella RM. Polycyclic aromatic hydrocarbon-DNA adducts in smokers and their relationship to micronutrient levels and the glutathione-S-transferase M1 genotype. Carcinogenesis 1994; 15:2449-2454.
15. Gonzalez, FJ. Genetic polymorphism and cancer susceptibility. Cancer Res 1995; 55:710-715.
16. Goto M, Yoneda S, Yamamoto M, Kawajiri K. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res 1996; 56:3725-3730.
17. Hayashi SI, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P4501A1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 1992; 83:866-870.
18. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Anttila S, Vainio H. Point-mutational Msp1 and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev 1992; 1:485-489.
19. Hirvonen A, Husgafvel-Pursiainen K, Anttilla S, Vainio H. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis 1993; 14:1479-1481.
20. Ichiba M, Hagmar L, Rannug A, Högstedt B, Alexandrie A-K, Carstensen U, Hemminki K. Aromatic DNA adducts, micronuclei and genetic polymorphism for CYP1A1 and GSTM1 in chimney sweeps. Carcinogenesis 1994; 15:1347-1352.
21. Idle JR. Is environmental Carcinogenesis modulated by host polymorphism? Mutat Res 1991; 247:259-266.
22. Kato S, Bowman ED, Harrington AM, Blomeke B, Shields P. Human lung carcinogen-DNA adducts levels mediated by genetic polymorphisms in vivo. J Natl Cancer Inst 1995; 87:902-907.
23. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphism of the cytochrome P4501A1 gene. FEBS Lett 1990; 263:131-133.
24. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol 1993; 14: 77-87.
25. Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M. Association of CYP1A1 germline polymorphism with mutations of the p53 gene in lung cancer. Cancer Res 1996; 56:72-76.
26. Ketterer B, Harris JM, Talaska G, Meyer DJ, Pemble SE, Taylor JB, Lang NP, Kadlubar FF. The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ Health Perspect 1992; 98:87-94.
27. Kihara M, Kihara M, Noda K. Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco exposure. Carcinogenesis 1994; 15:415-418.
28. Kihara M, Kihara M, Noda K. Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population. Carcinogenesis 1995; 16:2331-2336.
29. Kirby KS. A new method for the isolation of deoxyribonucleic acid. Biochem J 1957; 66:459-504.
30. London SJ, Daly AK, Cooper J, Navidi WC, Carpenter CL, Idle JR. Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. J Natl Cancer Inst 1995; 85:1246-1252.
31. McWilliams JE, Sanderson BJS, Harris EL, Richert-Boe KK, Henner WD. Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1995; 4: 589-594.
32. Mrozikiewicz PM, Cascorbi I, Brockmöller J, Roots I. CYP1A1 mutations 4887A, 4889G, 5639C and 6235C in the Polish population and their allelic linkage, determined by peptide nucleic acid-mediated PCR clamping. Pharmacogenetics 1997; 7:303-307.
33. Nakachi K, Imai K, Hayaschi S-I, Watanabe J, Kawajiri K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 1991; 51:5177-5180.
34. Nakachi K, Imai K, Hayashi S-I, Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 1993; 53:2994-2999.
35. Nazar-Stewart V, Motulski AG, Eaton DL, White E, Hornung SK, Leng ZT, Stapleton P, Weuss NS. The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res 1993; 53:2313-2318.
36. Nebert DW. Role of genetics and drug metabolism in human cancer risk. Mutat Res 1991; 247:267-281.
37. 32P-postlabeling and ELISA. Carcinogenesis 1994; 15:557-560.
38. Rojas M, Alexandrov K, Auburtin G, Wastiaux-Denamur A, Mayer L, Mahieu B, Sebastien P, Bartsch H. Anti-benzo[a]pyrene diolepoxide-DNA adduct levels in peripheral mononuclear cells from coke oven workers and the enhancing effect of smoking. Carcinogenesis 1995; 16:1373-1376.
39. Rothman N, Shields PG, Poirier MC, Harrington AM, Ford P, Strickland PT. The impact of glutathione S-transferase and cytochrome P450 1A1 genotypes on white blood cell polycyclic aromatic hydrocarbon-DNA adduct levels in humans. Mol Carcinogenesis 1995; 14:63-68.
40. Ryberg D, Hewer A, Phillips DH, Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 1994a; 54:5801-5803.
41. Ryberg D, Kure E, Lystad S, Skaug V, Stangeland L, Marcy I et al. P53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. Cancer Res 1994b; 54:1551-1555.
42. Ryberg D, Skaug V, Hewer A, Phillips DH, Harries LW, Wolf CR et al. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis 1997; 18:1285-1289.
43. Santella RM, Perera FP, Young TL, Zhang Y-J, Chiamprasert S, Tang D et al. Polycyclic aromatic hydrocarbon-DNA and protein adducts in coal tar treated patients and controls and their relationship to glutathione S-transferase genotype. Mutat Res 1995; 334:117-124.
44. Schoket B, Phillips DH, Kostic S, Vincze I. Smoking-associated bulky DNA adducts in bronchial tissue related to CYP1A1 Msp1 and GSTM1 genotypes in lung patients. Carcinogenesis 1998: 19:in press
45. Seidegard J, Pero R, Markowitz M, Roush G, Miller D, Beattie EJ. Isoenzymes of glutathione transferase (class Mu) as a marker for susceptibility to lung cancer: a follow up study. Carcinogenesis 1990; 11:33-36.
46. Severson RF, Snook ME, Arrendale RF, Chortuk OT. Gas chromatographic quantitation of polynuclear hydrocarbons in tobacco smoke. Anal Chem 1976; 48:1866-1872.
47. Shields PG, Bowman ED, Harrington AM, Doan VT, Weston A. Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res 1993; 53:5486-3492.
48. Tefre T, Ryberg D, Haugen A, Nebert DW, Skaug V, Brogger A, Børresen AL. Human CYP1A1 (cytochrome P-450) gene: lack of association between the Msp1 restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1991; 1:20-25.
49. Vaury C, Laine R, Noguiez P, Coppet P, Jaulin C, Praz F, Pompon D et al. Human glutathione S-transferase M1 null genotype is associated with high inducibility of cytochrome P4501A1 gene transcription. Cancer Res 1995; 55:5520-5523.
50. Zhang X-Y., Fasco MJ, Huang L, Guengerich P, Kaminsky LS. Characterisation of purified human recombinant cytochrome P4501A1-lle462 and Val462: assessment of a role for the rare allele in carcinogenesis. Cancer Res 1996; 56:3926-3933.
51. Zhong S, Howie AF, Ketterer B, Taylor J, Hayes JD, Beckett GJ, Wathen CG et al. Glutathione S-transferase n locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 1991; 12:1533-1537.